Positive new data for Pfizer's tofacitinib; possible regulatory delay
05:29 EDT 1 Aug 2012 | thePharmaLetter
Pfizer (NYSE:PFE), the world's largest drugmaker by sales, yesterday released positive top-line results from ORAL Start (A3921069), a Phase III study of the investigational agent tofacitinib, a novel, oral Janus kinase (JAK) inhibitor for the treatm..
Original Article: Positive new data for Pfizer's tofacitinib; possible regulatory delay
More From BioPortfolio on "Positive new data for Pfizer's tofacitinib; possible regulatory delay"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
